Strategy
Our path at NewBridge is defined by three strategic imperatives:
- Be the partner-of-choice and licensee for research-based pharmaceutics, biologics and genomic companies seeking to market their FDA and EMA/European approved products in the MENA Region; and providing them with a ”one-stop” and complete regional solution.
- Be the preferred partner for existing pharmaceutical companies in the region who solicit the services of NewBridge to further their brand equity and maintain their presence in the region.
- Introduce NewBridge’s own propriety brands complementary to our core business model and our existing portfolio.